[1] |
Chen Y, Griffiths C, Bulfone⁃Paus S. Exploring mast Cell⁃CD8 T cell interactions in inflammatory skin diseases[J]. Int J Mol Sci, 2023,24(2):1564. doi: 10.3390/ijms24021564.
|
[2] |
Zhang J, Zhang P, Ding Y, et al.Identification of key pathways and genes involved in psoriasis and vitiligo using bioinformatics analysis[J]. Int J Dermatol Venerol, 2023. doi:10.1097/JD9. 0000000000000337.
|
[3] |
Ching DW, Leibowitz MR. Ketotifen⁃⁃a therapeutic agent of eosinophilic fasciitis?[J]. J Intern Med, 1992,231(5):555⁃559. doi: 10.1111/j.1365⁃2796.1992.tb00974.x.
|
[4] |
Liu J, Xu Y, Lin TK, et al. Topical histamine stimulates repigmentation of nonsegmental vitiligo by a receptor⁃dependent mechanism[J]. Skin Pharmacol Physiol, 2017,30(3):139⁃145. doi: 10.1159/000464335.
|
[5] |
Khokhar D, Akin C. Mast cell activation: when the whole is greater than the sum of its parts[J]. Med Clin North Am, 2020,104(1):177⁃187. doi: 10.1016/j.mcna.2019.09.002.
|
[6] |
Akin C. Mast cell activation syndromes[J]. J Allergy Clin Immunol, 2017,140(2):349⁃355. doi: 10.1016/j.jaci.2017.06. 007.
|
[7] |
Aroni K, Voudouris S, Ioannidis E, et al. Increased angiogenesis and mast cells in the centre compared to the periphery of vitiligo lesions[J]. Arch Dermatol Res, 2010,302(8):601⁃607. doi: 10. 1007/s00403⁃010⁃1040⁃9.
|
[8] |
Berti S, Amato L, Arunachalam M, et al. Mast cells do not play a role in vitiligo[J]. Eur J Dermatol, 2011,21(5):800⁃801. doi: 10.1684/ejd.2011.1459.
|
[9] |
Min HK, Kim KW, Lee SH, et al. Roles of mast cells in rheumatoid arthritis[J]. Korean J Intern Med, 2020,35(1):12⁃24. doi: 10.3904/kjim.2019.271.
|
[10] |
Fang H, Zhang Y, Li N, et al. The autoimmune skin disease bullous pemphigoid: the role of mast cells in autoantibody⁃induced tissue injury[J]. Front Immunol, 2018,9:407. doi: 10. 3389/fimmu.2018.00407.
|
[11] |
Al C, Gallenga CE, Kritas SK, et al. Impact of mast cells in systemic lupus erythematosus: can inflammation be inhibited?[J]. J Biol Regul Homeost Agents, 2019,33(3):669⁃673.
|
[12] |
Grujic M, Paivandy A, Gustafson AM, et al. The combined action of mast cell chymase, tryptase and carboxypeptidase A3 protects against melanoma colonization of the lung[J]. Oncotarget, 2017,8(15):25066⁃25079. doi: 10.18632/oncotarget.15339.
|
[13] |
Bulfone⁃Paus S, Bahri R. Mast cells as regulators of T cell responses[J]. Front Immunol, 2015,6:394. doi: 10.3389/fimmu. 2015.00394.
|
[14] |
Cardamone C, Parente R, Feo GD, et al. Mast cells as effector cells of innate immunity and regulators of adaptive immunity[J]. Immunol Lett, 2016,178:10⁃14. doi: 10.1016/j.imlet.2016.07. 003.
|
[15] |
Becker M, Lemmermann NA, Ebert S, et al. Mast cells as rapid innate sensors of cytomegalovirus by TLR3/TRIF signaling⁃dependent and ⁃independent mechanisms[J]. Cell Mol Immunol, 2015,12(2):192⁃201. doi: 10.1038/cmi.2014.73.
|
[16] |
Yang L, Yang S, Lei J, et al. Role of chemokines and the corresponding receptors in vitiligo: a pilot study[J]. J Dermatol, 2018,45(1):31⁃38. doi: 10.1111/1346⁃8138.14004.
|
[17] |
Wong M, Uddin S, Majchrzak B, et al. Rantes activates Jak2 and Jak3 to regulate engagement of multiple signaling pathways in T cells[J]. J Biol Chem, 2001,276(14):11427⁃11431. doi: 10. 1074/jbc.M010750200.
|
[18] |
Zarrin AA, Bao K, Lupardus P, et al. Kinase inhibition in autoimmunity and inflammation[J]. Nat Rev Drug Discov, 2021,20(1):39⁃63. doi: 10.1038/s41573⁃020⁃0082⁃8.
|
[19] |
Ezzedine K, Peeva E, Yamaguchi Y, et al. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial[J]. J Am Acad Dermatol, 2023,88(2):395⁃403. doi: 10.1016/j.jaad.2022.11.005.
|